Lv1
40 积分 2022-10-17 加入
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
11天前
已完结
Unraveling MCL biology to understand resistance and identify vulnerabilities
11天前
已关闭
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
11天前
已完结
Real-worldimpactofdifferencesintheWHOandICCclassificationsofnon-Hodgkinlymphoma:aLEOcohortstudyanalysis
13天前
已关闭
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis
13天前
已关闭
Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation
29天前
已完结
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
1个月前
已完结
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia+
1个月前
已完结
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
1个月前
已关闭
皖公网安备34019202002308
